Detalles de la búsqueda
1.
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Eur J Haematol
; 109(3): 205-214, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35502600
2.
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
Eur J Haematol
; 106(3): 389-397, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33301613
3.
The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.
Pediatr Nephrol
; 36(4): 889-898, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33048203
4.
Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
Am J Transplant
; 19(10): 2865-2875, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31012541
5.
Automated Volumetry of Medial Temporal Lobe Subregions in Mild Cognitive Impairment and Alzheimer Disease.
Alzheimer Dis Assoc Disord
; 33(3): 206-211, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31135455
6.
Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome.
Kidney Int
; 94(2): 408-418, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29907460
7.
Japanese multicenter database of healthy controls for [123I]FP-CIT SPECT.
Eur J Nucl Med Mol Imaging
; 45(8): 1405-1416, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29478082
8.
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.
Blood
; 125(21): 3253-62, 2015 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25833956
9.
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Kidney Int
; 89(3): 701-11, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26880462
10.
Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Am J Kidney Dis
; 68(1): 84-93, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27012908
11.
Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.
Pediatr Nephrol
; 36(4): 1033, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33296010
12.
The global aHUS registry: methodology and initial patient characteristics.
BMC Nephrol
; 16: 207, 2015 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26654630
13.
Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria.
Pediatr Blood Cancer
; 61(9): 1544-50, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24777716
14.
Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria.
Blood Adv
; 8(11): 2813-2824, 2024 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38551806
15.
Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
Adv Ther
; 40(1): 211-232, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36272026
16.
Family support in assertive community treatment: an analysis of client outcomes.
Community Ment Health J
; 48(4): 463-70, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22002829
17.
Free water derived by multi-shell diffusion MRI reflects tau/neuroinflammatory pathology in Alzheimer's disease.
Alzheimers Dement (N Y)
; 8(1): e12356, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36304723
18.
Voxel-based analysis of age and gender effects on striatal [123I] FP-CIT binding in healthy Japanese adults.
Ann Nucl Med
; 36(5): 460-467, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35174441
19.
Factors associated with glycemic control and diabetes self-care among outpatients with schizophrenia and type 2 diabetes.
Arch Psychiatr Nurs
; 25(1): 63-73, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21251603
20.
The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.
J Pediatr
; 157(2): 282-7, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20400095